Cyclerion Therapeutics, Inc. (CYCN) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Cyclerion Therapeutics, Inc. (CYCN) Bundle
Looking to determine the intrinsic value of Cyclerion Therapeutics, Inc.? Our CYCN DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and make more informed investment choices.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.5 | 2.3 | 3.3 | .3 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | -49.06 | 44.6 | -91.05 | -100 | -48.88 | -48.88 | -48.88 | -48.88 | -48.88 |
EBITDA | -122.3 | -81.3 | -55.2 | -18.2 | -12.6 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | -2714.38 | -3539.42 | -1662.5 | -6121.55 | 100 | -60 | -60 | -60 | -60 | -60 |
Depreciation | 2.7 | 2.3 | .5 | .1 | -2.9 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 59.91 | 100.04 | 14.22 | 21.89 | 100 | 59.2 | 59.2 | 59.2 | 59.2 | 59.2 |
EBIT | -125.0 | -83.6 | -55.7 | -18.2 | -9.6 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | -2774.28 | -3639.46 | -1676.72 | -6143.43 | 100 | -60 | -60 | -60 | -60 | -60 |
Total Cash | 94.9 | 54.4 | 54.0 | 13.4 | 7.6 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 1.5 | .1 | .1 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 32.7 | 5.53 | 3.01 | 32.32 | 100 | 34.71 | 34.71 | 34.71 | 34.71 | 34.71 |
Inventories | 2.0 | .8 | .9 | .8 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 43.62 | 35.54 | 27.95 | 271.04 | 100 | 61.42 | 61.42 | 61.42 | 61.42 | 61.42 |
Accounts Payable | 3.3 | 1.4 | 1.8 | 3.0 | 1.2 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 73.46 | 62.5 | 55.06 | 1000 | 100 | 78.2 | 78.2 | 78.2 | 78.2 | 78.2 |
Capital Expenditure | -6.9 | -1.5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | -152.83 | -66.38 | -0.21084 | 0 | 100 | -33.32 | -33.32 | -33.32 | -33.32 | -33.32 |
Tax Rate, % | -66.88 | -66.88 | -66.88 | -66.88 | -66.88 | -66.88 | -66.88 | -66.88 | -66.88 | -66.88 |
EBITAT | -123.0 | -78.1 | -55.7 | -18.1 | -16.1 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -127.3 | -76.7 | -54.9 | -16.8 | -19.9 | -1.2 | .0 | .0 | .0 | .0 |
WACC, % | 13.53 | 13.53 | 13.53 | 13.53 | 13.53 | 13.53 | 13.53 | 13.53 | 13.53 | 13.53 |
PV UFCF | ||||||||||
SUM PV UFCF | -1.1 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -1 | |||||||||
Net Debt | -8 | |||||||||
Equity Value | 7 | |||||||||
Diluted Shares Outstanding, MM | 2 | |||||||||
Equity Value Per Share | 2.79 |
What You Will Get
- Real CYCN Financial Data: Pre-filled with Cyclerion Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Cyclerion’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Customizable Clinical Parameters: Adjust key inputs such as trial success rates, market penetration, and R&D expenditures.
- Instant Drug Development Valuation: Computes intrinsic value, NPV, and other metrics in real-time.
- Industry-Leading Precision: Incorporates Cyclerion's actual financial data for accurate valuation results.
- Effortless Scenario Planning: Evaluate various assumptions and analyze results with ease.
- Efficiency Booster: Remove the necessity of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Cyclerion Therapeutics’ pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions.
Why Choose This Calculator for Cyclerion Therapeutics, Inc. (CYCN)?
- User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
- Customizable Inputs: Modify parameters effortlessly to suit your financial analysis.
- Real-Time Valuation: Instantly observe changes in Cyclerion's valuation with input adjustments.
- Preloaded Data: Comes with Cyclerion's actual financial metrics for swift evaluations.
- Endorsed by Industry Experts: Utilized by investors and analysts for well-informed decision-making.
Who Should Use This Product?
- Investors: Accurately assess Cyclerion Therapeutics’ fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial analysis and reporting.
- Consultants: Efficiently customize the template for client valuation reports.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation techniques.
What the Template Contains
- Historical Data: Includes Cyclerion Therapeutics’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Cyclerion Therapeutics’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Cyclerion Therapeutics’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.